Mumbai: Mankind Pharma Limited has acquired Bharat Serums and Vaccines Limited (BSV) with an aim to position itself as a leader in the Indian women’s health and fertility drug market while also enhancing its portfolio in the critical care segment. BSV’s established R&D platforms and specialized product range are expected to provide a significant boost to Mankind’s capabilities.
BSV, with over 50 years of experience in biopharmaceuticals, is renowned for its recombinant and niche biologic products. It holds a strong presence in women’s health, fertility, critical care, and immunoglobulins, with products like Thymogam and Octaplex leading the market. Mankind aims to leverage this expertise to expand its reach in India and global markets.
Sheetal Arora, Chief Executive Officer (CEO) and Whole-time Director of Mankind Pharma, highlighted the opportunities presented by the acquisition, particularly in the fertility sector. Meanwhile, BSV’s CEO and Managing Director, Sanjiv Navangul, emphasized that joining Mankind Pharma will help unlock new opportunities and enhance the availability of complex treatments to patients worldwide.
